SCHEMBL6482423

SCHEMBL6482423

Cc1cc2ccccc2n1NC(=O)C1CC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 3/20 0.59
▸ HSD17B10 Q99714 3/20 0.53
▸ MEN1 O00255 2/20 0.53
▸ KMT2A Q03164 2/20 0.53
▸ ALOX15 P16050 2/20 0.53
▸ CASP1 P29466 2/20 0.53
▸ CYP1A2 P05177 1/20 0.53
▸ CYP3A4 P08684 1/20 0.53
▸ CYP2D6 P10635 1/20 0.53
▸ CYP2C19 P33261 1/20 0.53
▸ KDM4E B2RXH2 5/20 0.52
▸ ALDH1A1 P00352 5/20 0.52
▸ SMN1; SMN2 Q16637 2/20 0.52
▸ POLB P06746 1/20 0.52
▸ THRB P10828 1/20 0.52
▸ SLC6A2 P23975 1/20 0.44
▸ GAA P10253 1/20 0.44
▸ HPGD P15428 3/20 0.43
▸ TP53 P04637 2/20 0.43
▸ MTNR1A P48039 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6480184 0.94 MEN1 (0.57) TSHRHSD17B10MEN1KMT2AALOX15
SCHEMBL6480068 0.94 MEN1 (0.60) TSHRHSD17B10MEN1KMT2AALOX15
SCHEMBL6480930 0.93 ALDH1A1 (0.61) TSHRHSD17B10MEN1KMT2AALOX15
SCHEMBL31465692 0.73 MAPT (0.48) TSHRHSD17B10MEN1KMT2ACYP1A2
SCHEMBL6188501 0.73 TSHR (0.40) TSHRHSD17B10MEN1KMT2AALOX15
SCHEMBL31465676 0.72 KDM4E (0.46) TSHRHSD17B10MEN1KMT2AALOX15
SCHEMBL31465664 0.72 KDM4E (0.43) TSHRHSD17B10MEN1KMT2AALOX15
SCHEMBL31465662 0.71 KDM4E (0.43) TSHRHSD17B10MEN1KMT2AALOX15
SCHEMBL6488982 0.71 KMT2A (0.49) TSHRHSD17B10MEN1KMT2AALOX15
SCHEMBL31465674 0.70 MAPT (0.45) TSHRHSD17B10MEN1KMT2ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050215614-A1 Substituted indoles and their use as hcv inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2005-09-29 — — US claimed
US-20050215614-A1 Substituted indoles and their use as hcv inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2005-09-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050215614-A1 Substituted indoles and their use as hcv inhibitors IDO1, IDO2, HAVCR2 TSHR 3228/4885HSD17B10 980/4885MEN1 4842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback